News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Protherics starts trial of brain cancer therapy

Posted on: 03/29/2007

Protherics starts trial of brain cancer therapy

LONDON (AFX) - Small-cap drug developer Protherics PLC has enrolled the first patient in a clinical study to investigate the use of OncoGel, a reformulation of the chemotherapy agent paclitaxel, in brain cancer.

The trial will examine the drug as an adjuvant treatment to surgical removal of the tumour in patients with recurrent glioblastoma multiforme, the most common and most aggressive primary brain tumour.

The illness, which affects between 18,000-20,000 patients in the US and EU a year, recurs in approximately 90 pct of people after initial surgery and radiation therapy.

OncoGel is a localised therapy designed to achieve a high concentration of paclitaxel, a proven and widely used agent, at the site of the tumour for up to six weeks.

The study will investigate the safety and tolerability of OncoGel, administered into the cavity produced through surgical removal of the tumour, and enrol up to 36 patients.

Preliminary data is expected in the second half of 2007, and data from all patients at the end of 2008.

OncoGel has already produced encouraging phase 2a data in oesophageal cancer. ab

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557